In another retrospective cohort of 195 women with metastatic breast cancer treated at the MD Anderson Cancer Center, including 30 BRCA1- and 11 BRCA2-associated breast cancer receiving various treatments, BRCA non-carriers and BRCA2 carriers had a longer time-to progression and OS compared to BRCA1 carriers (median time-to progression = 1.3 vs. 0.9 vs. 0.7 years, p = 0.31, and median OS = 4.88 vs. 4.94 vs. 1.34 years, p = 0.0065, respectively). Here, BRCA1 is linked to breast carcinoma.